Track EWTX and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Edgewise Therapeutics Inc
1715 38th Street, Boulder, CO, United States, 80301
IPO
2021
Employees
154
Industry
Biotechnology
Sector
Healthcare
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q2 20261-1
0
Q1 20261-1
0
Q4 202510
1
Q3 20256-6
0
Q2 20255-5
0
5-quarter cumulative
14 sells1 buys
Analyst Ratings
5 analysts covering
Buy60%recommend buy
Buy
3
Hold
2
Sell
0